{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Table 4:', 'Bleed Management Dosing Guidelines by Specific Product', 'Factor IX', 'Factor IX', 'Recombinant', 'Factor VIII', 'Standard half-', 'Extended half-', 'aPCC', 'Factor VIIa', 'life', 'life', 'Recommended', 'single dose of', '10 IU/kg', '20 IU/kg', '20 IU/kg', '30 U/kg', '<45 g/kg', 'Single Dose', 'should not', '20 IU/kg', '30 IU/kg', '30 IU/kg', '50 U/kg', '45 g/kg', 'exceed', 'Repeat dose', 'Mandatory to call the clinical study center prior to second dose', 'Mandatory to', 'instructions', 'Consider evaluation and treatment at the clinical study center', 'call site prior to', '(see Section 6.4)', 'third dose', 'Should not', 'Should not', 'Should not', 'Should not repeat', 'Should not repeat', 'repeat in less', 'repeat in less', 'repeat', 'in less than', 'in less than', 'than', 'than', 'in less than', '24 hours', '24 hours', '5-7 days', '24 hours', '2 hours', 'Should be seen at site within 48-72 hours if more', 'Should be seen', 'than 2 doses are required', 'at site within', '48-72 hours if', '(see Schedule of Assessments for assessments)', 'more than 3', 'doses are', 'required', 'For situations requiring higher doses, more frequent administration, multiple repeated doses, discussion with', 'study Medical Monitor and Clinical Advisor is recommended, and AT replacement should be considered.', 'Do not use antifibrinolytics in combination with factor or BPA.', 'Note: Doses of FVIII and FIX are included for completeness. It is expected that these inhibitor patients will be', 'routinely managed with rFVIIa or aPCC for bleeding episodes. Adjunctive management of bleeding episodes', 'should be carried out per standard of care.', '6.3.1.3.', 'Bleeding Episode Management Following Discontinuation of Fitusiran', 'Patients who opt to discontinue fitusiran may resume standard on-demand dosing with BPAs', 'when their AT residual activity level returns to approximately 60% (per the central laboratory).', 'An earlier restart of standard treatment may be considered in conjunction with consultation from', 'the study Medical Monitor, if a strong medical need arises (eg, increased frequency of bleeding).', 'If full doses of factor or BPA are required to achieve hemostasis prior to full AT recovery', '(approximately 60% residual activity per the central laboratory), AT replacement should be', 'considered.', '6.3.2.', 'Other Concomitant Medications', 'If patients use nonsteroidal anti-inflammatory drugs intermittently or chronically, they must be', 'able to tolerate them and have had no previous side effects (eg, gastric distress or bleeding).', 'Property of the Sanofi Group - strictly confidential', '49']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Use of >4 g acetaminophen per day is not permitted.', 'Treatment for HIV is permitted and must be recorded as concomitant medication.', 'Standard vitamins and topical medications are permitted. However, topical steroids must not be', 'applied anywhere near the injection site(s) unless medically indicated.', \"Any concomitant medication that is required for the patient's welfare may be prescribed by the\", 'Investigator. However, it is the responsibility of the Investigator to ensure that details regarding', 'the medication are recorded on the eCRF. Concomitant medication will be coded using an', 'internationally recognized and accepted coding dictionary.', '6.4.', 'Assessment of Coagulation Parameters at the Time of a Bleed', 'Any patient who presents to the clinical study center for evaluation of symptoms that are', 'suspected as characteristic of a bleeding episode, the patient should be assessed by the', 'Investigator to determine whether symptom(s) require treatment. If treatment is required, blood', 'samples should be collected predose and postdose and assessments performed as scheduled in', 'Table 2.', 'If a patient presents following administration of factor or BPAs at home and within 48 hours of', 'the dose, and no further treatment is given at the center, AT and the postdose assessments', 'in', 'Table 2 should be obtained in a single draw at any time during the visit.', '6.5.', 'Monitoring and Management of Thrombotic Events', \"Given safety events observed thus far and the possible thrombotic risk associated with fitusiran's\", 'AT lowering mechanism, which may be increased with concurrent use of factor replacement', 'products or BPAs, there should be a low threshold to evaluate any signs and symptoms', 'consistent with thrombosis, including symptoms consistent with cerebral venous sinus', 'thrombosis (CVST). Symptoms of thrombosis may include a severe or persistent headache,', 'headache with nausea and vomiting, chest pain/tightness, coughing up blood, trouble breathing,', 'abdominal pain, fainting or loss of consciousness, vision problems, and swelling or pain in the', 'arms or legs.', 'If signs and symptoms consistent with thrombosis are present, the Investigator should evaluate', 'the patient for thrombosis, including appropriate imaging studies. For the diagnosis of CVST', 'magnetic resonance imaging venogram (MRV) or computed tomography venogram (CTV) are', 'recommended.', 'If a patient develops a thrombosis while on fitusiran, AT reversal is recommended in', 'combination with factor or BPA replacement and appropriate anticoagulation. AT reversal', 'should follow labeled product recommendations for the prevention of perioperative thrombosis', 'in patients with AT deficiency, and patient doses individualized to target 80-120% AT activity.', 'The use of plasma derived AT may be preferable to recombinant AT, given its longer half-life.', 'It is recommended that cases of thrombosis are discussed with the study Medical Monitor and', 'Clinical Advisor (see Section 7.5.6.1 for further information regarding Adverse Events of', 'Special Interest).', 'Property of the Sanofi Group - strictly confidential', '50']\n\n###\n\n", "completion": "END"}